[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atopy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atopy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100301592","niaid-centralized-sequencing-protocol-100301592",false,"NCT03206099","NIAID Centralized Sequencing Protocol","* PARTICIPANT INCLUSION CRITERIA:\n* Must fulfill one of the following criteria:\n\n  * Proband participants: must be individuals under investigation by another NIH protocol on which they are co-enrolled, or are referred from the GDMCC protocol \"Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults\" (NCT04702243). Probands may have a disease under investigation or be healthy volunteers\n  * Biological relatives: biologically related to a proband participant.\n* Aged 0-99 years.\n* Participants must be willing to undergo genetic testing.\n* Participants must be willing to allow samples to be stored for future research.\n* Participants must be willing to have their de-identified genomic data shared, for example in a controlled access databases like the Database of Genotypes and Phenotypes (dbGaP).\n* To complete surveys and interviews:\n\n  * Proficient with the English language.\n  * Able to provide informed consent.\n* Adult healthy volunteers must be able to provide informed consent.\n\nPARTICIPANT EXCLUSION CRITERIA:\n\nAny condition that, in the opinion of the investigator, contraindicates participation in this study is a reason for exclusion.",true,"ALL","1 Day","100 Years",{"count":20,"type":21},20000,"ESTIMATED","OBSERVATIONAL","Background:\n\nGenetic testing called \"sequencing\" helps researchers look at DNA. Genes are made of DNA and are the instructions for our bodies to function. We all have thousands of genes. DNA variants are differences in genes between two people. We all have lots of variants. Most are harmless and some cause differences like blue or brown eyes. A few variants can cause health problems.\n\nObjective:\n\nTo understand the genetics of immune disorders various health conditions, as well as outcomes of clinical genomics and genetic counseling services performed under this protocol.\n\nEligibility:\n\nParticipants in other NIH human subjects research protocols - either at the NIH Clinical Center (CC) or at Children s National Health System (CNHS) - (aged 0-99 years), and, in select cases, their biological relatives\n\nDesign:\n\nResearchers will study participant s DNA extracted from blood, saliva, or another tissue sample, including previously collected samples we may have stored at the NIH. Researchers will look at participant s DNA in great detail. We are looking for differences in the DNA sequence or structure between participants and other people.\n\nParticipants will receive results that:\n\n* Are important to their health\n* Have been confirmed in a clinical lab\n* Suggest that they could be at risk for serious disease that may affect your current or future medical management.\n\nSome genetic information we return to participants may be of uncertain importance.\n\nIf genetic test results are unrelated to the participant s NIH evaluations, then we will not typically report:\n\n* Normal variants\n* Information about progressive, fatal conditions that have no effective treatment\n* Carrier status (conditions you don t have but could pass on)\n\nThe samples and data will be saved for future research.\n\nPersonal data will be kept as private as possible.\n\nIf future studies need new information, participants may be contacted.",[25,26,27,28],"Atopy","Primary Immunodeficiency","Autoimmunity","Autoinflammation",[30,31,32,33,34,35],"Phenotyping","Genetics","Sequencing","Inborn Errors of Immunity","Genomics","Natural History","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2017-07-31",{"date":44,"type":21},"2029-12-31",{"name":46,"class":47},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100464774","phase-2-omalizumab-before-onset-of-exacerbations-100464774","NCT05332067","Omalizumab Before Onset of Exacerbations","OBOE","Inclusion Criteria at Study Entry:\n\nParticipants must meet the following:\n\n1. Parent or guardian must be able to understand and provide informed consent in English and participants ≥7 must be able to provide assent\n2. 6-17 years, inclusive at time of screening\n3. Physician-diagnosed persistent asthma\n4. ≥1 exacerbation of asthma requiring systemic corticosteroids in the 6-month period before the planned start of the participant's upcoming school year or ≥2 exacerbations of asthma requiring systemic corticosteroids in the 12-month period before the planned start of the participant's upcoming school year\n5. Sensitization to ≥1 perennial aeroallergen\n6. Total serum IgE and weight appropriate for omalizumab dosing\n7. Insurance that covers standard of care medications\n8. Primary family residence (home where child sleeps a majority of nights) in a Metropolitan Statistical Area where ≥10% of families have income below poverty line and\u002For publicly funded health insurance\n9. At least one of the following criteria:\n\n   1. peripheral eosinophilia \\>300µL\n   2. total serum IgE \\>300kU\u002FL\n   3. sensitization to ≥3 perennial aeroallergens\n10. Females of childbearing potential must have a negative pregnancy test upon study entry\n11. Females with reproductive potential must agree to use FDA approved methods of birth control for the duration of the study\n\nAdditional Inclusion Criteria (these must be met prior to randomization at the fall season sick visit A (SVa) during the 90-day outcome period):\n\nIn order to be eligible for randomization at the SVa visit, participants must also meet all of the following criteria:\n\n1. Reporting onset of URI symptoms within 72 hours prior to SVa, confirmed by the study physician\n2. Report no use of nasal corticosteroids or nasal vaccinations within 14 days prior to SVa\n3. Have a negative rapid nasal swab antigen test for SARS-CoV-2\n4. Be more than 14 days from the onset of any previous asthma exacerbation requiring systemic steroids\n5. Have no current lower respiratory symptoms that, in the opinion of the study physician, require systemic corticosteroid treatment\n6. Complete collection of nasal absorption sample within 72 hours of onset URI \\[defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms)\\] as determined by the study physician's assessment at the SVa visit\n\nExclusion Criteria:\n\n1. Inability or unwillingness of a participant's parent or guardian to give written informed consent or comply with study protocol or inability or unwillingness of a participant ≥7 to provide assent\n2. Contraindication to receipt of omalizumab\n3. Presence of a second chronic medical condition (including but not limited to serious cardiorespiratory disorders, cancer, sickle cell disease, uncontrolled seizure disorder, auto-immune disorders, or type 1 diabetes)\n4. Pregnancy or active lactation\n5. History of latex allergy\n6. Treatment with omalizumab or other monoclonal antibody, or aeroallergen immunotherapy in the prior six months\n7. Plan for home schooling during the 90-day outcome period\n8. History of life-threatening asthma defined by requirement for intubation or cardiorespiratory arrest\n9. Inability of primary caregiver and child to speak English\n10. In the opinion of the investigator, participant will not be able to wean from nasal steroids or to avoid nasal vaccinations during the 90-day fall outcome period\n11. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study","6 Years","17 Years",{"count":58,"type":21},300,"INTERVENTIONAL",[61],"PHASE2","OBOE is a prospective, pilot, parallel group RCT with the overall aim of examining the effect of a single dose of anti-IgE (omalizumab) vs. placebo administered at the onset of URIs in the fall season among highly exacerbation-prone, urban, and atopic youth aged 6-17 years with persistent asthma. OBOE will recruit and randomize participants over 3 years (3 annual cohorts of participants). Recruitment for each of the yearly cohorts of OBOE will begin in February. Each cohort will be followed for a 2-6-month run-in period with the objective to gain control of each participant's asthma and to stabilize the required controller medication step level. Participants will receive routine asthma care every 1-2 months (a total of 2-4 times) during run-in using a previously described algorithm developed by the Inner-city Asthma Consortium and successfully employed in the PROSE study. The primary outcome is the change in the amount of nasal IFN-α recovered by nasal fluid absorption between two time points, within 72 hours of onset of a URI as defined by onset of (or substantial worsening of) rhinorrhea, nasal congestion or sneezing (single or multiple symptoms) and 3-6 days after study drug injection.",[64,25,65],"Asthma in Children","Viral Upper Respiratory Infection","2025-07-10",{"date":68,"type":40},"2025-07-14",{"date":70,"type":40},"2022-05-01",{"date":72,"type":21},"2028-03-01",{"name":74,"class":75},"Children's National Research Institute","OTHER",1]